Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Minerva Neurosciences Q3 2024 GAAP EPS $2.97 May Not Be Comparable To $(1.01) Estimate

Author: Benzinga Newsdesk | November 05, 2024 08:04am

Minerva Neurosciences (NASDAQ:NERV) reported quarterly earnings of $2.97 per share which may not be comparable to analyst consensus estimate of $(1.01). This is a 388.35 percent increase over losses of $(1.03) per share from the same period last year.

Posted In: NERV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist